Advertisement
Advertisement
ENTX
Entera Bio Ltd. Ordinary Shares
1.30
USDSponsored
-0.07
-5.11%
May 08, 15:59 UTC -4
Closed
After-Market
1.29
-0.01
-0.69%
ENTX Earnings Reports
Positive Surprise Ratio
ENTX beat 23 of 30 last estimates.
77%
Next Report
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.17
Implied change from Q1 26 (Revenue/ EPS)
--
/+142.86%
Implied change from Q2 25 (Revenue/ EPS)
--
/+183.33%
Entera Bio Ltd. Ordinary Shares earnings per share and revenue
On May 08, 2026, ENTX reported earnings of -0.07 USD per share (EPS) for Q1 26, beating the estimate of -0.15 USD, resulting in a 54.25% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.17 USD, with revenue projected to reach -- USD, implying an increase of 142.86% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
FAQ
What were Entera Bio Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Entera Bio Ltd. Ordinary Shares reported EPS of -$0.07, beating estimates by 54.25%, and revenue of $0.00, -- -- expectations.
How did the market react to Entera Bio Ltd. Ordinary Shares's Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Entera Bio Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for Entera Bio Ltd. Ordinary Shares's next earnings report?
Based on 3
analysts, Entera Bio Ltd. Ordinary Shares is expected to report EPS of -$0.17 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement